Titre:
  • EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.
Auteur:Hamilton, Andrew; Roy, J A; Beex, Louk; Piccart-Gebhart, Martine; Mauriac, L; Coleman, R; Paridaens, R.; Boes, G H; Van Vreckem, A; Palmer, P; Klijn, J
Informations sur la publication:Breast cancer research and treatment, 60, 2, page (181-188)
Statut de publication:Publié, 2000-03
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Antineoplastic Agents, Hormonal -- adverse effects
Antineoplastic Agents, Hormonal -- pharmacology
Antineoplastic Agents, Hormonal -- therapeutic use
Breast Neoplasms -- chemistry
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Disease-Free Survival
Drug Resistance, Neoplasm
Female
Humans
Imidazoles -- adverse effects
Imidazoles -- pharmacology
Imidazoles -- therapeutic use
Middle Aged
Postmenopause
Receptors, Estrogen -- analysis
Treatment Outcome
Note générale:Clinical Trial
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0167-6806
info:pmid/10845281